Pharmaceutical Business review

Encorium signs $5 million new contracts

The therapeutic areas included in these awards are cardiovascular diseases, oncology, diabetes, and infectious diseases. Services, which will be provided in both North America and Europe, include medical/scientific consulting, data management, regulatory affairs, project management, field monitoring, and medical monitoring/writing.

Revenue recognition for many of these contracts will begin in the current third quarter of 2008 with the remainder expected to occur on a proportional performance basis as services are performed on each project.

Kenneth Borow, president of Encorium, said: “Encorium has announced approximately $10 million of new business contracts during the past week which has resulted in an increase in our current backlog of signed contracts to approximately $43 million.

“We are very encouraged by these recent developments and remain confident in our ability to continue to win new business across a wide array of therapeutic areas and geographies.”